139 related articles for article (PubMed ID: 15849223)
61. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
62. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
[TBL] [Abstract][Full Text] [Related]
63. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
64. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
65. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
[TBL] [Abstract][Full Text] [Related]
66. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
67. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Sherry RM; Topalian SL; Restifo NP; Royal RE; Kammula U; White DE; Mavroukakis SA; Rogers LJ; Gracia GJ; Jones SA; Mangiameli DP; Pelletier MM; Gea-Banacloche J; Robinson MR; Berman DM; Filie AC; Abati A; Rosenberg SA
J Clin Oncol; 2005 Apr; 23(10):2346-57. PubMed ID: 15800326
[TBL] [Abstract][Full Text] [Related]
68. Temozolomide in resistant or relapsed pediatric solid tumors.
De Sio L; Milano GM; Castellano A; Jenkner A; Fidani P; Dominici C; Donfrancesco A
Pediatr Blood Cancer; 2006 Jul; 47(1):30-6. PubMed ID: 16047361
[TBL] [Abstract][Full Text] [Related]
69. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group.
Ettinger LJ; Gaynon PS; Krailo MD; Ru N; Baum ES; Siegel SE; Hammond GD
Cancer; 1994 Feb; 73(4):1297-301. PubMed ID: 8313334
[TBL] [Abstract][Full Text] [Related]
70. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
71. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
72. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
[TBL] [Abstract][Full Text] [Related]
73. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R
Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446
[TBL] [Abstract][Full Text] [Related]
74. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
[TBL] [Abstract][Full Text] [Related]
75. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
[TBL] [Abstract][Full Text] [Related]
76. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
Okuno K; Ohnishi H; Koh K; Shindo H; Yoshioka H; Yasutomi M
Biotherapy; 1992; 4(4):257-65. PubMed ID: 1622739
[TBL] [Abstract][Full Text] [Related]
77. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Margolin KA; Rayner AA; Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Doroshow JH; Jaffe HS; Roper M
J Clin Oncol; 1989 Apr; 7(4):486-98. PubMed ID: 2647914
[TBL] [Abstract][Full Text] [Related]
78. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS
Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826
[TBL] [Abstract][Full Text] [Related]
79. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
80. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.
Margolin KA; Van Besien K; Wright C; Niland J; Champlin R; Fung HC; Kashyap A; Molina A; Nademanee AP; O'Donnell MR; Parker P; Smith E; Spielberger R; Somlo G; Snyder D; Stein A; Woo D; Thomas M; Sniecinski I; Forman SJ
Biol Blood Marrow Transplant; 1999; 5(1):36-45. PubMed ID: 10232739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
